Centre imposes price capping on coronary stents, hospitals f
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
Get authentic, real-time news that helps you fight COVID-19 better.
Install PlexusMD App for doctors. It's free.
In February this year, the National Pharmaceutical Pricing Authority (NPPA) had reduced prices of coronary stents by up to 85% and yet the cost of angioplasties has more or less remained the same, indicating that the benefit was not passed on to the patients by the hospitals.

Hospitals have now increased the cost of treatment, the consultancy fee, added miscellaneous expenses and the angioplasty procedure has also been made chargeable now.

Interestingly, drug pricing regulator NPPA ruled out the mid-term revision of coronary stent prices, saying it would revisit the matter in February 2018 after taking into consideration all related issues.

While capping the price of the stents, the government had made it mandatory for stent makers to maintain production and supply of coronary stents by invoking an emergency clause under drug price control law citing reports of shortage in the market. However, this was opposed by medical device makers at that time as they believed that this move could limit the accessibility of cutting-edge technologies in coronary stents for Indian patients, affecting both treatment quality and risking the high-growth medical tourism sector...

http://timesofindia.indiatimes.com/india/centre-imposes-price-capping-on-coronary-stents-hospitals-find-a-way-around-it/articleshow/60855138.cms
Preview
Like
Comment
Share